<DOC>
	<DOCNO>NCT00994799</DOCNO>
	<brief_summary>This study investigate hypothesis ranibizumab injection give eye efficacious safe treatment option apply swell macula ( site sharp vision ) diabetes .</brief_summary>
	<brief_title>Comparison Intravitreal Ranibizumab Macular Grid-pattern Laser Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>This randomize , control , three-center trial ass efficacy safety intravitreal ranibizumab injection diabetic macular edema . Comparator arm consist patient receive macular grid-pattern laser therapy .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female type I II diabetic patient 18 year age Diagnosis DME secondary diabetic retinopathy decrease vision due DME due cause opinion investigator Patients BCVA score 78 39 letter study eye use ETDRSlike visual acuity chart test distance 4 meter Expectation investigator patient potentially benefit laser treatment ranibizumab treatment Willing able comply study procedure Active intraocular inflammation , active infection history uveitis Uncontrolled glaucoma neovascularization iris study eye Structural damage within 0.5 disc diameter center macula study eye likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) , epiretinal membrane involve fovea organize hard exudate plaque Concurrent disease study eye could compromise visual acuity prevent improvement visual acuity ( include diabetic proliferative retinopathy ) require medical surgical intervention study period , include cataract , retinal vascular occlusion , retinal detachment , macular hole choroidal neovascularization cause Panretinal laser photocoagulation study eye within 6 month prior study focal/grid laser photocoagulation study eye within 3 month prior study entry Treatment antiangiogenic drug ( pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , etc ) intravitreal corticosteroid study eye within 3 month prior randomization Any intraocular surgery study eye within 3 month prior randomization History vitrectomy study eye Ocular condition study eye require chronic concomitant therapy topical ocular systemically administer corticosteroid Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>